MCID: PRP080
MIFTS: 53

Peripheral Artery Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Peripheral Artery Disease

MalaCards integrated aliases for Peripheral Artery Disease:

Name: Peripheral Artery Disease 12 15
Peripheral Arterial Diseases 71
Peripheral Arterial Disease 43

Classifications:



External Ids:

Disease Ontology 12 DOID:0050830
MeSH 43 D058729
UMLS 71 C1704436

Summaries for Peripheral Artery Disease

Disease Ontology : 12 An artery disease that is characterized by build up of plaque in the arteries that carry blood to your head, organs, and limbs.

MalaCards based summary : Peripheral Artery Disease, also known as peripheral arterial diseases, is related to peripheral vascular disease and intermittent claudication, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Peripheral Artery Disease is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Nebivolol and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and bone, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 74 Peripheral artery disease (PAD) is an abnormal narrowing of arteries other than those that supply the... more...

Related Diseases for Peripheral Artery Disease

Diseases related to Peripheral Artery Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 597)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 33.4 VWF VEGFA VCAM1 SELP NOS3 IL6
2 intermittent claudication 32.0 VWF VEGFA SELP IL6 CRP ACE
3 hyperlipoproteinemia, type iii 31.6 APOE APOB APOA1
4 end stage renal failure 31.2 SELP IL6 CST3 CRP APOB ACE
5 peripheral nervous system disease 31.1 VEGFA IL6 CRP CCL2 ACE
6 arteriosclerosis obliterans 31.1 VCAM1 SELP IL6 ICAM1
7 chlamydia 31.0 IL6 CRP CCL2
8 impotence 31.0 NOS3 EDN1 ACE
9 limb ischemia 31.0 VWF VEGFA NOS3 IL6 ICAM1 FGF2
10 cardiogenic shock 30.9 IL6 CRP
11 pulmonary disease, chronic obstructive 30.9 IL6 CRP CCL2 ACE
12 hypercholesterolemia, familial, 1 30.9 PCSK9 NOS3 CRP APOE APOB APOA1
13 ischemia 30.8 VEGFA SELP NOS3 ICAM1 FGF2 EDN1
14 atrial fibrillation 30.8 VWF SELP NOS3 IL6 CRP ACE
15 platelet aggregation, spontaneous 30.8 VWF SELP
16 aortic aneurysm 30.8 IL6 CRP CDKN2B-AS1 APOE ACE
17 chlamydia pneumonia 30.7 IL6 CRP APOE
18 hypertriglyceridemia, familial 30.7 APOE APOB APOA1
19 lipid metabolism disorder 30.7 PCSK9 IL6 CRP CCL2 APOE APOB
20 chronic ulcer of skin 30.7 VEGFA IL6 FGF2 CRP
21 active peptic ulcer disease 30.6 VWF P2RY12 CRP
22 hyperglycemia 30.6 VCAM1 NOS3 IL6 APOB
23 diabetic neuropathy 30.6 VEGFA ICAM1 FGF2 ACE
24 angina pectoris 30.6 NOS3 IL6 EDN1 CRP APOA1 ACE
25 renovascular hypertension 30.6 NOS3 EDN1 ACE
26 decubitus ulcer 30.6 VEGFA IL6 FGF2 CRP
27 thrombosis 30.6 VWF VCAM1 SELP P2RY12 NOS3
28 aortic disease 30.5 IL6 CRP APOE ACE
29 tricuspid valve insufficiency 30.5 EDN1 CRP ACE
30 generalized atherosclerosis 30.5 VWF IL6 CRP APOE APOB ACE
31 renal artery disease 30.5 NOS3 CST3 CRP ACE
32 antiphospholipid syndrome 30.5 VWF VCAM1 SELP CRP
33 polyneuropathy 30.5 VEGFA IL6 CRP APOA1 ACE
34 temporal arteritis 30.5 IL6 CRP CCL2
35 left bundle branch hemiblock 30.5 P2RY12 CRP ACE
36 periodontitis, chronic 30.5 TNFRSF11B IL6
37 deficiency anemia 30.4 SELP IL6 CST3 CRP ACE
38 bone disease 30.4 VEGFA TNFRSF11B IL6 ICAM1 CCL2
39 cerebral atherosclerosis 30.4 CRP APOE APOA1 ACE
40 carotid artery disease 30.4 SELP CRP CCL2 APOE APOB APOA1
41 cerebrovascular disease 30.4 VWF VCAM1 SELP IL6 ICAM1 CRP
42 chronic venous insufficiency 30.4 VEGFA VCAM1 SELP ICAM1 CRP
43 diabetic polyneuropathy 30.4 VEGFA NOS3 APOB
44 glomerulonephritis 30.3 VCAM1 ICAM1 CCL2 ACE
45 raynaud disease 30.3 EDN1 CRP ACE
46 non-alcoholic fatty liver disease 30.3 IL6 CRP APOB APOA1
47 collagen disease 30.3 VWF IL6 EDN1 CRP ACE
48 heart valve disease 30.3 VWF EDN1 CRP ACE
49 uremia 30.3 VWF TNFRSF11B IL6 CRP ACE
50 congestive heart failure 30.3 VEGFA NOS3 IL6 EDN1 CRP CDKN2B-AS1

Graphical network of the top 20 diseases related to Peripheral Artery Disease:



Diseases related to Peripheral Artery Disease

Symptoms & Phenotypes for Peripheral Artery Disease

UMLS symptoms related to Peripheral Artery Disease:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.35 APOA1 APOB APOE PCSK9 SELP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE SELP

MGI Mouse Phenotypes related to Peripheral Artery Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.36 ACE APOA1 APOB APOE CRP CST3
2 homeostasis/metabolism MP:0005376 10.3 ACE APOA1 APOB APOE CRP CST3
3 cellular MP:0005384 10.21 APOA1 APOB APOE FGF2 ICAM1 IL6
4 hematopoietic system MP:0005397 10.18 ACE APOE FGF2 ICAM1 IL6 NOS3
5 immune system MP:0005387 10.13 ACE APOB APOE CCL2 CRP ICAM1
6 mortality/aging MP:0010768 10 ACE APOB APOE CST3 EDN1 FGF2
7 liver/biliary system MP:0005370 9.91 ACE APOA1 APOB APOE IL6 NOS3
8 muscle MP:0005369 9.61 APOB APOE CST3 EDN1 FGF2 ICAM1
9 nervous system MP:0003631 9.36 APOB APOE CST3 EDN1 FGF2 ICAM1

Drugs & Therapeutics for Peripheral Artery Disease

Drugs for Peripheral Artery Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 418)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Ezetimibe Approved Phase 4 163222-33-1 150311
6
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
7
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
8
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
9
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
10
Methyltestosterone Approved Phase 4 58-18-4 6010
11
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
12
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
13
Testosterone enanthate Approved Phase 4 315-37-7 9416
14
Defibrotide Approved, Investigational Phase 4 83712-60-1
15
Dalteparin Approved Phase 4 9005-49-6
16
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
17
Triflusal Approved, Investigational Phase 4 322-79-2
18
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
19
Ramipril Approved Phase 4 87333-19-5 5362129
20
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
21
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
22
Empagliflozin Approved Phase 4 864070-44-0
23
Glimepiride Approved Phase 4 93479-97-1 3476
24
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
25
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
26
Allopurinol Approved Phase 4 315-30-0 2094
27
Febuxostat Approved Phase 4 144060-53-7 134018
28
Rivaroxaban Approved Phase 4 366789-02-8
29
Verapamil Approved Phase 4 52-53-9 2520
30
Liraglutide Approved Phase 4 204656-20-2 44147092
31
Glucagon Approved Phase 4 16941-32-5
32
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
33
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
34
Metformin Approved Phase 4 657-24-9 14219 4091
35
tannic acid Approved Phase 4 1401-55-4
36
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
37
Atorvastatin Approved Phase 4 134523-00-5 60823
38
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
39
Pravastatin Approved Phase 4 81093-37-0 54687
40
Zinc Approved, Investigational Phase 4 7440-66-6 32051
41
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
42
Insulin glargine Approved Phase 4 160337-95-1
43
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
44
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
45
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
46
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
47
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
49
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
50
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731

Interventional clinical trials:

(show top 50) (show all 1329)
# Name Status NCT ID Phase Drugs
1 SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial Unknown status NCT02959606 Phase 4 Sarpogrelate SR 300mg;Clopidogrel
2 Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions Unknown status NCT01969630 Phase 4
3 Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix Unknown status NCT02279784 Phase 4
4 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Unknown status NCT02563535 Phase 4
5 Estimation de la capacité Fonctionnelle à la Marche Par Questionnaire Clinique Chez Les Patients adressés Pour Bilan artériel Des Membres inférieurs Unknown status NCT01424020 Phase 4
6 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
7 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
8 Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy Unknown status NCT01095549 Phase 4
9 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
10 Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
11 A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease Unknown status NCT01711333 Phase 4 Pletaal SR capsule
12 Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects. Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
13 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
14 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
15 Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis. Unknown status NCT00711984 Phase 4
16 Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications Unknown status NCT02581904 Phase 4
17 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
18 EVALUATION OF THE RELATIONSHIP BETWEEN EFFERVESCENT PARACETAMOL AND BLOOD PRESSURE. CLINICAL TRIAL. Unknown status NCT02514538 Phase 4 Non- effervescent Paracetamol kern;Effervescent paracetamol termalgin
19 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
20 Jetstream NAVITUS™ System Endovascular Therapy Post-market Registry (JET) Completed NCT01436435 Phase 4
21 A Prospective, Single-Arm Study to Evaluate the Effects of the Jetstream G3 System on Calcified Peripheral Vascular Lesions Completed NCT01273623 Phase 4
22 Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization Completed NCT01983449 Phase 4 Dexamethasone Sodium Phosphate Injection, USP
23 A Prospective, Randomized, Multicenter Comparison of Balloon Angioplasty and the Cypher Selecttm + Coronary and Infrapopliteal Stent in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease Completed NCT00640770 Phase 4
24 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD Completed NCT01952756 Phase 4 Cilostazol;Dummy Placebo
25 Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication Completed NCT00822172 Phase 4 cilostazol
26 Intermittent Mechanical Compression For Peripheral Arterial Disease Completed NCT00855673 Phase 4 Control
27 Non-Randomized, Prospective, Multi-center Evaluation of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System for Occluded or Stenotic Superficial Femoral or Proximal Popliteal Arteries Completed NCT00180505 Phase 4
28 Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS) Completed NCT00231738 Phase 4 Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
29 The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease Completed NCT00168467 Phase 4 Ramipril
30 Phase IV Study of Statins for Assess the Long-term Pleiotropic Effect Upon Nitric Oxide and C-Reactive Protein Levels in Patients With Peripheral Arterial Disease Completed NCT01041729 Phase 4 Atorvastatin;Standard Medical Treatment
31 Drug Eluting Balloon in peripherAl inTErvention: the DEBATE SFA Study Completed NCT01556542 Phase 4
32 Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis Completed NCT01083030 Phase 4
33 Investigation of the Arterial Effects of the Veinoplus(r) Stimlator Device. Completed NCT01592812 Phase 4
34 Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease. Completed NCT00431249 Phase 4 Cilostazol
35 Intra-individual Efficacy Evaluation of DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Lower Limb Arterial Diseases Completed NCT00955617 Phase 4
36 NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions Completed NCT01783600 Phase 4
37 The Jetstream G2 System Post-Market Peripheral Vascular IVUS Study Completed NCT00911417 Phase 4
38 Physician-Initiated Trial Investigating the Efficacy of Endovascular Treatment of Femoropopliteal Arterial Stenotic Disease With the Biotronik Passeo-18 Lux Drug Releasing Balloon and the Biotronik Pulsar-18 Stent (Comparing With 4EVER Trial Results) Completed NCT02211664 Phase 4
39 DURABILITY-POP Study - Physician Initiated Trial Investigating the Efficacy of the Implant of Protégé EverFlex Nitinol Stents in Popliteal Lesions Completed NCT01412450 Phase 4
40 Efficacy Evaluation of Dotarem®-Enhanced MRA Compared to Gadovist®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Limb Arterial Diseases Completed NCT01026389 Phase 4 Dotarem;Gadovist
41 Effect of Plavix Treatment on NO Production Measured by Laser Doppler Method Referring to Endothelial Function in Patients With Severe Coronary Heart Disease Completed NCT00648453 Phase 4 Clopidogrel (Plavix)
42 BeSmooth Study, a Physician-initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions Completed NCT02690051 Phase 4
43 DURABILITY+ : a Prospective, Multi-center, Controlled Study Measuring the Durability in Lesions of the Superficial Femoral Artery of the Protégé Everflex+ Stent Completed NCT01412463 Phase 4
44 The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study) Completed NCT01188824 Phase 4 Cilostazol
45 ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease Completed NCT00681226 Phase 4 Ramipril or matching placebo
46 GORE VIABAHN Endoprosthesis Versus Bare Nitinol Stent in the Treatment of Long Lesion (>8cm) Superficial Femoral Artery Occlusive Disease Completed NCT00228384 Phase 4
47 Femoral Artery In-Stent Restenosis (FAIR) Trial Completed NCT01305070 Phase 4
48 The Effect of Angioplasty in Peripheral Arterial Disease on Endothelial Function Completed NCT00660634 Phase 4
49 A Randomised, Double Blind, Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus Completed NCT00504712 Phase 4 Testosterone;saline
50 ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg Completed NCT00442845 Phase 4 Atorvastatin (Lipitor)

Search NIH Clinical Center for Peripheral Artery Disease

Cochrane evidence based reviews: peripheral arterial disease

Genetic Tests for Peripheral Artery Disease

Anatomical Context for Peripheral Artery Disease

MalaCards organs/tissues related to Peripheral Artery Disease:

40
Heart, Endothelial, Bone, Kidney, Testes, Skin, Bone Marrow

Publications for Peripheral Artery Disease

Articles related to Peripheral Artery Disease:

(show top 50) (show all 4903)
# Title Authors PMID Year
1
Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis. 61
31950864 2020
2
The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). 61
31845593 2020
3
Predictive value of the combination of brachial-ankle pulse wave velocity and ankle-brachial index for cardiovascular outcomes in patients with acute myocardial infarction. 61
31821193 2020
4
Effects of heated water-based versus land-based exercise training on vascular function in individuals with peripheral artery disease. 61
32027542 2020
5
Impact of diabetes mellitus on 5-year clinical outcomes following successful endovascular revascularization for peripheral artery disease. 61
31690244 2020
6
Retinal microvascular findings and risk of incident peripheral artery disease: An analysis from the Atherosclerosis Risk in Communities (ARIC) Study. 61
31812251 2020
7
Does Creatine Supplementation Affect Renal Function in Patients with Peripheral Artery Disease? A Randomized, Double Blind, Placebo-controlled, Clinical Trial. 61
31563660 2020
8
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. 61
31615291 2020
9
Financial barriers in accessing medical care for peripheral artery disease are associated with delay of presentation and adverse health status outcomes in the United States. 61
31603393 2020
10
Trends in statin utilization among adults with severe peripheral artery disease including critical limb ischemia in an integrated healthcare delivery system. 61
31512991 2020
11
Adherence to Guideline-Recommended Therapy-Including Supervised Exercise Therapy Referral-Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry. 61
31973609 2020
12
Impact of Sex on Survival and Neurologic Outcomes in Adults With In-Hospital Cardiac Arrest. 61
31791546 2020
13
Preprocedural Cross-Sectional Imaging Prior to Percutaneous Peripheral Arterial Disease Interventions. 61
31746279 2020
14
The Geriatric Nutritional Risk Index Predicts Long-Term Survival and Cardiovascular or Limb Events in Peripheral Arterial Disease. 61
31217396 2020
15
Marine and plant-based n-3 PUFA and atherosclerotic cardiovascular disease. 61
30982476 2020
16
The Prevention of Cardiovascular Disease in Older Adults. 61
32031247 2020
17
Using the epidemiology of critical limb ischemia to estimate the number of patients amenable to endovascular therapy. 61
31621531 2020
18
Acute Heart Failure Comorbidome: The Impact of Everything Else. 61
32035496 2020
19
Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization. 61
32029132 2020
20
Practical Applications of Tack Implants for Infrainguinal Dissection Repair: A Single-Center Experience. 61
31637955 2020
21
Factors Influencing in-Stent Occlusion after Femoropopliteal Artery Stent Placement with Intravascular Ultrasound Evaluation. 61
31883937 2020
22
Association of comorbid depression with inpatient outcomes in critical limb ischemia. 61
31713461 2020
23
Comparative Outcomes of Supera Interwoven Nitinol vs Bare Nitinol Stents for the Treatment of Femoropopliteal Disease: Insights From the XLPAD Registry. 61
31686573 2020
24
Prevalence and correlates of statin underuse for secondary prevention of cardiovascular disease in older adults 65-79 years of age. The Italian Health Examination Survey 2008-2012. 61
32008438 2020
25
Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population. 61
32024471 2020
26
Long-term outcome upon treatment of calcified lesions of the lower limb using scoring angioplasty balloon (AngioSculpt™). 61
32036430 2020
27
A case of ischemic osteopathy in a hemodialysis patient with advanced peripheral artery disease. 61
31637589 2020
28
Nutritional Status as a Predictor of Clinical Prognosis in Patients with Peripheral Artery Disease. 61
31189760 2020
29
Lower Limb Arterial Calcification and Acute Thrombosis Risk in Patients with Peripheral Artery Disease. 61
31536790 2020
30
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. 61
31783279 2020
31
Vascular Disease Patient Information Page: Exercise for peripheral artery disease. 61
31830869 2020
32
Utilization and Outcomes of Local Anesthesia and Peripheral Nerve Block for Hybrid Lower Extremity Revascularization. 61
31746264 2020
33
Corrigendum to "Real Life Lessons in Peripheral Artery Disease - A Priority for Public Healthcare" [Eur J Vasc Endovasc Surg 59 (1) (2020) 5-6]. 61
32008933 2020
34
Real-World Predictors of Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients with Chronic Coronary Artery Disease and/or Peripheral Arterial Disease. 61
31705434 2020
35
Effect of footplate neuromuscular electrical stimulation on functional and quality-of-life parameters in patients with peripheral artery disease: pilot, and subsequent randomized clinical trial. 61
31912491 2020
36
Different association between renal dysfunction and clinical outcomes according to the presence of diabetes in patients undergoing endovascular treatment for peripheral artery disease. 61
31285068 2020
37
Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials. 61
31756624 2020
38
Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease. 61
31785493 2020
39
Using maximal systolic acceleration to diagnose and assess the severity of peripheral artery disease in a flow model study. 61
31147131 2020
40
Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial. 61
32000630 2020
41
Association of 4-limb systolic blood pressure heterogeneity with peripheral artery disease and left ventricular mass index. 61
32011439 2020
42
Correlation of Severity of Peripheral Artery Disease (PAD) in Diabetic Patient with 10 Year Atherasclerotic Cardiovascular Risk Score (ASCVD). 61
31979556 2020
43
Industry compensation and self-reported financial conflicts of interest among authors of highly cited peripheral artery disease studies. 61
31980241 2020
44
Exclusion of Persons with Kidney Disease in Trials of Peripheral Artery Disease: A Systematic Review of Randomized Trials. 61
31888921 2020
45
Fasting plasma glucose variability and HbA1c are associated with peripheral artery disease risk in type 2 diabetes. 61
31910828 2020
46
2017 ACC/AHA blood pressure classification and incident peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) Study. 61
31362534 2020
47
Quantitative evaluation of postintervention foot blood supply in patients with peripheral artery disease by computed tomography perfusion. 61
31964575 2020
48
Initial financial impact of office-based laboratories on Medicare payments for percutaneous interventions for peripheral artery disease. 61
31973948 2020
49
Efficacy of optical frequency-domain imaging in detecting peripheral artery disease: a single-center open-label, single-arm study protocol. 61
31898308 2020
50
Histological Evidence for Therapeutic Induction of Angiogenesis Using Mast Cells and Platelet-Rich Plasma within A Bioengineered Scaffold following Rat Hindlimb Ischemia. 61
31376320 2020

Variations for Peripheral Artery Disease

Expression for Peripheral Artery Disease

Search GEO for disease gene expression data for Peripheral Artery Disease.

Pathways for Peripheral Artery Disease

Pathways related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 VWF VEGFA VCAM1 TNFRSF11B NOS3 IL6
2
Show member pathways
13.32 VWF VEGFA VCAM1 TNFRSF11B IL6 ICAM1
3
Show member pathways
13.27 VWF VEGFA SELP P2RY12 NOS3 APOB
4
Show member pathways
12.62 VEGFA VCAM1 NOS3 ICAM1 CCL2
5
Show member pathways
12.33 VEGFA VCAM1 NOS3 ICAM1 CCL2
6 12.04 VEGFA VCAM1 IL6 FGF2
7 11.97 SELP IL6 ICAM1 CCL2
8
Show member pathways
11.95 PCSK9 APOE APOB APOA1
9 11.94 VEGFA VCAM1 NOS3 ICAM1 EDN1 CCL2
10 11.9 VEGFA NOS3 IL6 EDN1
11 11.85 VCAM1 IL6 ICAM1 EDN1 CCL2
12
Show member pathways
11.83 IL6 ICAM1 CRP CCL2 APOE APOB
13 11.79 VEGFA IL6 ICAM1 CCL2
14 11.76 VWF NOS3 FGF2 CCL2
15 11.69 VEGFA VCAM1 IL6 ICAM1 FGF2 CCL2
16
Show member pathways
11.58 VEGFA VCAM1 IL6 ICAM1
17 11.56 VEGFA NOS3 EDN1
18 11.56 IL6 FGF2 EDN1 CCL2
19 11.5 IL6 ICAM1 CCL2
20 11.49 VEGFA IL6 FGF2
21 11.45 TNFRSF11B IL6 APOE
22 11.45 VCAM1 NOS3 ICAM1
23 11.42 SELP IL6 ICAM1 APOB
24 11.35 VCAM1 SELP IL6 ICAM1 CCL2
25 11.31 NOS3 IL6 CCL2
26 11.27 CCL2 APOE ACE
27 11.24 VCAM1 IL6 ICAM1 APOA1
28
Show member pathways
11.22 VEGFA EDN1 CRP
29 11.17 VEGFA VCAM1 NOS3 IL6 ICAM1 EDN1
30 11.09 VEGFA NOS3 FGF2
31 10.87 VCAM1 ICAM1 CCL2

GO Terms for Peripheral Artery Disease

Cellular components related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 10.08 P2RY12 NOS3 IL6 ICAM1 FGF2 EDN1
2 cell surface GO:0009986 10.01 VEGFA VCAM1 PCSK9 P2RY12 ICAM1 APOA1
3 external side of plasma membrane GO:0009897 9.95 VCAM1 SELP P2RY12 ICAM1 ACE
4 early endosome GO:0005769 9.89 VCAM1 PCSK9 APOE APOB APOA1
5 extracellular region GO:0005576 9.8 VWF VEGFA TNFRSF11B PCSK9 IL6 FGF2
6 endoplasmic reticulum lumen GO:0005788 9.73 PCSK9 IL6 CST3 APOE APOB APOA1
7 high-density lipoprotein particle GO:0034364 9.63 APOE APOB APOA1
8 very-low-density lipoprotein particle GO:0034361 9.61 APOE APOB APOA1
9 endocytic vesicle lumen GO:0071682 9.58 APOE APOB APOA1
10 low-density lipoprotein particle GO:0034362 9.54 APOE APOB APOA1
11 extracellular space GO:0005615 9.53 VEGFA VCAM1 TNFRSF11B SELP PCSK9 IL6
12 Weibel-Palade body GO:0033093 9.52 VWF EDN1
13 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
14 chylomicron GO:0042627 9.5 APOE APOB APOA1
15 intermediate-density lipoprotein particle GO:0034363 9.33 APOE APOB APOA1

Biological processes related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.01 VEGFA NOS3 IL6 CRP CDKN2B-AS1 APOB
2 angiogenesis GO:0001525 10 VEGFA NOS3 FGF2 CCL2
3 in utero embryonic development GO:0001701 9.99 VEGFA NOS3 EDN1 APOB
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 ICAM1 FGF2 CCL2 APOE
5 negative regulation of gene expression GO:0010629 9.97 VEGFA EDN1 CDKN2B-AS1 APOE ACE
6 response to hypoxia GO:0001666 9.93 VEGFA VCAM1 ICAM1 EDN1
7 post-translational protein modification GO:0043687 9.93 PCSK9 IL6 CST3 APOE APOB APOA1
8 cytokine-mediated signaling pathway GO:0019221 9.91 VEGFA VCAM1 IL6 ICAM1 FGF2 CCL2
9 steroid metabolic process GO:0008202 9.9 PCSK9 APOE APOB APOA1
10 extracellular matrix organization GO:0030198 9.89 VWF VCAM1 TNFRSF11B ICAM1 FGF2
11 platelet degranulation GO:0002576 9.88 VWF VEGFA SELP APOA1
12 response to nutrient GO:0007584 9.87 VCAM1 TNFRSF11B APOA1
13 cholesterol homeostasis GO:0042632 9.85 PCSK9 APOE APOB APOA1
14 regulation of blood pressure GO:0008217 9.84 NOS3 EDN1 ACE
15 retinoid metabolic process GO:0001523 9.84 APOE APOB APOA1
16 positive regulation of MAP kinase activity GO:0043406 9.83 VEGFA FGF2 EDN1
17 cholesterol metabolic process GO:0008203 9.81 PCSK9 APOE APOB APOA1
18 positive regulation of blood vessel endothelial cell migration GO:0043536 9.8 VEGFA NOS3 FGF2
19 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.8 VCAM1 SELP ICAM1
20 cellular response to tumor necrosis factor GO:0071356 9.8 VCAM1 ICAM1 EDN1 CCL2 APOB
21 leukocyte cell-cell adhesion GO:0007159 9.73 VCAM1 SELP ICAM1
22 cellular protein metabolic process GO:0044267 9.73 PCSK9 IL6 CST3 APOE APOB APOA1
23 high-density lipoprotein particle clearance GO:0034384 9.7 APOE APOA1
24 artery morphogenesis GO:0048844 9.7 VEGFA APOE APOB
25 chylomicron remnant clearance GO:0034382 9.69 APOE APOB
26 very-low-density lipoprotein particle remodeling GO:0034372 9.68 APOE APOA1
27 negative regulation of lipid storage GO:0010888 9.68 IL6 CRP
28 positive regulation of cholesterol esterification GO:0010873 9.68 APOE APOA1
29 negative regulation of platelet activation GO:0010544 9.68 NOS3 APOE
30 neutrophil mediated immunity GO:0002446 9.67 IL6 ACE
31 negative regulation of hydrolase activity GO:0051346 9.65 NOS3 APOA1
32 regulation of Cdc42 protein signal transduction GO:0032489 9.65 APOE APOA1
33 very-low-density lipoprotein particle clearance GO:0034447 9.65 APOE APOB
34 cholesterol efflux GO:0033344 9.65 APOE APOB APOA1
35 negative regulation of cellular protein metabolic process GO:0032269 9.64 EDN1 APOE
36 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.64 NOS3 EDN1
37 lipoprotein catabolic process GO:0042159 9.62 APOE APOB
38 membrane to membrane docking GO:0022614 9.61 VCAM1 ICAM1
39 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.61 VEGFA ACE
40 positive regulation of phospholipid efflux GO:1902995 9.59 APOE APOA1
41 positive regulation of low-density lipoprotein particle receptor catabolic process GO:0032805 9.58 PCSK9 APOE
42 chylomicron assembly GO:0034378 9.54 APOE APOB APOA1
43 chylomicron remodeling GO:0034371 9.5 APOE APOB APOA1
44 lipoprotein biosynthetic process GO:0042158 9.33 APOE APOB APOA1
45 lipoprotein metabolic process GO:0042157 9.26 PCSK9 APOE APOB APOA1
46 response to lipopolysaccharide GO:0032496 9.1 VCAM1 SELP NOS3 ICAM1 EDN1 APOB

Molecular functions related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.71 VWF VCAM1 ICAM1 FGF2
2 amyloid-beta binding GO:0001540 9.67 CST3 APOE APOA1
3 heparin binding GO:0008201 9.55 VEGFA SELP FGF2 APOE APOB
4 lipid transporter activity GO:0005319 9.5 APOE APOB APOA1
5 lipoprotein particle binding GO:0071813 9.48 APOE APOA1
6 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.46 APOE APOA1
7 very-low-density lipoprotein particle receptor binding GO:0070326 9.43 PCSK9 APOE
8 intermembrane cholesterol transfer activity GO:0120020 9.43 APOE APOB APOA1
9 cytokine activity GO:0005125 9.43 VEGFA TNFRSF11B IL6 FGF2 EDN1 CCL2
10 apolipoprotein receptor binding GO:0034190 9.37 PCSK9 APOA1
11 low-density lipoprotein particle receptor binding GO:0050750 8.92 PCSK9 CRP APOE APOB

Sources for Peripheral Artery Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....